EUVIMED · CrossrefZeitschrift
Cancer Drug Resistance
ISSN 2578-532X · OAE Publishing Inc.
Neueste Artikel
Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies
Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance
Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters
MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy
Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies
Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma
Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies
KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer
The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy
ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment
Mechanism of ferroptosis resistance in cancer cells
NFE2L2 and ferroptosis resistance in cancer therapy
Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy
Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer
The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β
Recent advanced lipid-based nanomedicines for overcoming cancer resistance
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Supramolecular host-guest nanosystems for overcoming cancer drug resistance
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
Mitochondria in colorectal cancer stem cells - a target in drug resistance
Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects
Anti-BCMA novel therapies for multiple myeloma
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
EUVIMED